Featured Research

from universities, journals, and other organizations

New therapeutic combination to slow resistant sarcomas

Date:
July 10, 2014
Source:
IDIBELL-Bellvitge Biomedical Research Institute
Summary:
A new therapeutic combination to combat resistant sarcomas have been tested in 19 patients in a recent study. The clinical trial results indicate that the new treatment could stabilize the growth of these tumors. Sarcomas are a rare type of tumor, and are complex since there are several subtypes. They can affect anyone from childhood onward.

Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) have been tested in 19 patients a new therapeutic combination to combat resistant sarcomas. The clinical trial results, which indicate that the new treatment could stabilize the growth of these tumors have been published this week in the British Journal of Cancer.

Sarcomas

Sarcomas are a rare type of tumor and complex since there are several subtypes. It can affect from children to older ages. It is usually diagnosed in advanced and very little localized phases. So the 50% cured with major surgeries and localized treatment. But the other 50% is resistant to conventional therapies and ends metastasizing.

The IDIBELL research group in sarcomas, led by Oscar Martinez-Tirado, investigate to test new drugs or new combinations of drugs that could be more effective against these tumors and for that works closely with the coordinator of the Unit of Sarcomas at ICO, Javier García del Muro. This teamwork joins the most basic research to the most clinical and has led in this case to bring the results of research from bench to bedside.

Conventional chemotherapy and targeted therapy

Researchers tested different combinations of conventional chemotherapy with new drugs aimed at molecular targets in cell sarcomas and decided to try in mice a combination of conventional chemotherapy used to treat these tumors and rapamycin, a drug that acts specifically in mTOR, an altered protein in various types of cancer.

"With the results in the cell lines we thought it was the best option to test in mice," said Martinez-Tirado "but the truth is that the results in animals were spectacular. In mice that had the tumor and we gave to them this combination, the tumor stopped growing and weeks after stopping treatment it was not recovered, as it does if we treat them with chemotherapy alone or only with rapamycin. "

Responsible for this phase I clinical trial has been Javier García del Muro. It has been tested this new combination in nineteen patients, most of sarcoma but also included patients with other tumor types that have no treatment. "Although Phase I trials are used to determine the recommended dose and discard toxicities, we have seen that the combination is active in various tumor types, as we have seen prolongated stabilizations in advanced and resistant tumors to chemotherapy" .

With these encouraging results, the group has launched a phase II clinical trial. "We have completed the recruitment of patients, in this case, only sarcomas, to test whether this combination really works in these patients and whether it is better than current treatments."


Story Source:

The above story is based on materials provided by IDIBELL-Bellvitge Biomedical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Juan Martin-Liberal, Marta Gil-Martín, Miguel Sáinz-Jaspeado, Nuria Gonzalo, Raul Rigo, Helena Colom, Carmen Muñoz, Oscar M Tirado and Xavier García del Muro. Phase I study of sirolimus plus gemcitabine in solid tumors. British Journal of Cancer, July 2014

Cite This Page:

IDIBELL-Bellvitge Biomedical Research Institute. "New therapeutic combination to slow resistant sarcomas." ScienceDaily. ScienceDaily, 10 July 2014. <www.sciencedaily.com/releases/2014/07/140710111900.htm>.
IDIBELL-Bellvitge Biomedical Research Institute. (2014, July 10). New therapeutic combination to slow resistant sarcomas. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2014/07/140710111900.htm
IDIBELL-Bellvitge Biomedical Research Institute. "New therapeutic combination to slow resistant sarcomas." ScienceDaily. www.sciencedaily.com/releases/2014/07/140710111900.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) — Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins